AryoGen Pharmed

Executive Summary

AryoGen Pharmed is a private Israeli biotech company founded in 2020, focused on developing next-generation biologics for oncology and immunology. Leveraging its proprietary antibody discovery and engineering platform, the company generates fully human monoclonal antibodies and antibody-drug conjugates (ADCs) targeting high-unmet medical needs. With $30 million raised to date, AryoGen is currently in the preclinical stage, building a robust pipeline of candidates that aim to improve treatment outcomes for patients with cancer and immune disorders. The company's platform combines innovative antibody engineering with deep biological insights, enabling the creation of differentiated therapeutics. AryoGen has advanced its lead ADC program toward IND-enabling studies, demonstrating promising preclinical efficacy and safety profiles against a novel tumor antigen. The team of 50-200 employees is experienced in biologics development, positioning the company to achieve near-term milestones. Upcoming catalysts include regulatory filings for its lead candidate, preclinical data presentations at major conferences, and potential strategic partnerships. While still early-stage, AryoGen's strong platform and focused approach offer significant upside potential for investors seeking exposure to innovative biologics.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead ADC candidate40% success
• Q3 2026Presentation of preclinical data at major oncology conference70% success
• Q2 2026Announcement of strategic partnership or licensing deal30% success